(4R)-4-乙基-2-恶唑烷酮 | 98974-04-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4R)-4-乙基-2-恶唑烷酮
• 英文名称: (4R)-4-ethyl-1,3-oxazolidin-2-one
• 英文别名: (R)-(+)-4-ethyl-2-oxazolidinone；(R)-4-ethyl-oxazolidin-2-one；(R)-4-ethyl-2-oxazolidinone；(R)-4-ethyloxazolidin-2-one；(4R)-4-ethyl-oxazolidin-2-one；4R-ethyl-oxazolidin-2-one
• CAS: 98974-04-0
• 化学式: C₅H₉NO₂
• mdl: MFCD00068849
• 分子量: 115.132
• InChiKey: CRHQYASHOICRND-SCSAIBSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

SDS

Name:	(4R)-4-Ethyl-2-oxazolidinone Material Safety Data Sheet
Synonym:
CAS:	98974-04-0

Section 1 - Chemical Product MSDS Name:(4R)-4-Ethyl-2-oxazolidinone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
98974-04-0	(4R)-4-Ethyl-2-oxazolidinone		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 98974-04-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H9NO2
Molecular Weight: 115.13

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 98974-04-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4R)-4-Ethyl-2-oxazolidinone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 98974-04-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 98974-04-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 98974-04-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4R)-4-乙基-2-恶唑烷酮 在 三氟甲磺酸三甲基硅酯 、 D(+)-10-樟脑磺酸 、 四氯化锡 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 3.0h， 生成 (2R,4R)-2-[(4R)-4-ethyl-2-oxo-1,3-oxazolidin-3-yl]-4-phenyl-3,4-dihydro-2H-pyran-6-carboxylic acid methyl ester
  参考文献：
  名称：

  路易斯酸使用β取代的N-乙烯基恶唑烷酮调节面部立体发散的HDA反应。

  摘要：

  新的β-取代的N-乙烯基-1,3-恶唑烷-2-酮（具有R'= Me，Ar，CH2 Ar）与β，γ-不饱和α-酮酸酯（[4 + 2]酸催化的杂环加成）之间（ R = Ar）提供具有高水平的内和面选择性的杂加合物。通过改变路易斯酸可以完全逆转面部分化，从而导致内-α或内-β加合物的立体选择性形成。[反应：请参见文字]。

  DOI：

  10.1021/ol062626l
• 作为产物：
  描述：

  (4R,2'R,3'S)-N-(3-hydroxy-2-methylbutanoyl)-4-ethyl-2-oxazolidinone 在 lithium hydroxide 、 双氧水 作用下， 以82%的产率得到(4R)-4-乙基-2-恶唑烷酮
  参考文献：
  名称：

  外消旋助剂：在不对称合成中的应用

  摘要：

  外消旋助剂已成功用于实现不对称合成。外消旋的Evans aldol产品得自具有良好非对映控制性的外消旋酰基恶唑烷酮。外消旋醇醛产物的对映体通过脂肪酶催化的酰化反应拆分。水解得到对映体富集的恶唑烷酮和对映体富集的β-羟基酸。

  DOI：

  10.1016/s0040-4039(02)00722-0

文献信息

• BENZOXAZEPIN OXAZOLIDINONE COMPOUNDS AND METHODS OF USE
  申请人：Genentech, Inc.

  公开号：US20170002022A1

  公开（公告）日：2017-01-05

  Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.

  本发明描述了具有磷脂酰肌醇-3激酶（PI3K）调节活性的苯并恶唑啉恶唑烷酮化合物，其具有如下公式I结构：或其立体异构体、互变异构体或药用可接受的盐，以及本发明所述的取代基和结构特征。还描述了包括公式I化合物的药物组合物和药物，以及使用这样的PI3K调节剂的方法，单独使用或与其他治疗剂联合使用，用于治疗由PI3K失调介导或依赖的疾病或病症。
• Synthesis of Ring-Fused Oxazolo- and Pyrazoloisoquinolinones by a One-Pot Pd-Catalyzed Carboxamidation and Aldol-Type Condensation Cascade Process
  作者：Gagan Chouhan、Howard Alper

  DOI：10.1021/jo9010574

  日期：2009.8.21

  three-component cascade process is described for the synthesis of ring-fused oxazolo- and pyrazoloisoquinolinones by a one-pot carboxamidation/aldol-type condensation reaction. The cascade process involves Pd-catalyzed carboxamidation of an aryl halide/active methylene compound with oxazolidinone or pyrazolidinone, and subsequent intramolecular base-catalyzed cyclization/dehydration through an aldol-type

  描述了通过单锅羧酰胺化/醛醇缩合反应合成环稠合的恶唑啉和吡唑异喹啉酮的三组分级联方法。级联过程涉及芳基卤化物/活性亚甲基化合物与恶唑烷酮或吡唑烷酮的钯催化羧酰胺化，以及随后的分子内碱催化的醛醇缩合环化/脱水，以产生环稠合的恶唑啉代和吡唑并异喹啉酮。这种方法为这些重要的含氮杂环类化合物提供了一种简单的一步方法，并且可以耐受各种官能团，包括酯，腈，甲氧基和卤化物。
• Substituted benzo[b]pyrans, processes for their preparation, their use
  申请人：Hoechst Aktiengesellschaft

  公开号：US05130310A1

  公开（公告）日：1992-07-14

  Benzo[b]pyran derivatives of the formula I ##STR1## with E--D equal to CH--CHOH or C.dbd.CH; X equal to oxygen or sulfur; Y equal to oxygen, sulfur, SO, SO.sub.2 or NR.sup.9 ; R.sup.1 equal to CN, NO.sub.2, Hal, alkoxycarbonyl, SO.sub.1-2 -alkyl or SO.sub.1-2 -aryl; R.sup.2 equal to H, OH, alkoxy, alkyl, Hal, NR.sup.10 R.sup.11 ; R.sup.3 /R.sup.4 equal to alkyl; R.sup.5 /R.sup.6 equal to alkyl, (CH.sub.2).sub.1-6 COO-alkyl, (CH.sub.2).sub.1-6 CONR.sup.10 R.sup.11, (CH.sub.2).sub.0-6 COOH, (CH.sub.2).sub.1-6 CO-alkyl, CO.sub.2 -alkyl, alkylmercaptoalkyl, alkylsulfi(i)(o)nyl, hydroxyalkyl, mercaptoalkyl, aminoalkyl, N-(di)-alkylaminoalkyl or (CH.sub.2).sub.f Ar with f equal to zero-3; R.sup.7 /R.sup.8 equal to hydrogen, alkyl or phenyl, and m equal to zero-2 are outstanding antihypertensives and spasmolytics. Preparation processes and use are described.

  公式I的Benzo[b]pyran衍生物##STR1##，其中E--D等于CH--CHOH或C.dbd.CH；X等于氧或硫；Y等于氧、硫、SO、SO.sub.2或NR.sup.9；R.sup.1等于CN、NO.sub.2、Hal、烷氧羰基、SO.sub.1-2-烷基或SO.sub.1-2-芳基；R.sup.2等于H、OH、烷氧基、烷基、Hal、NR.sup.10 R.sup.11；R.sup.3 /R.sup.4等于烷基；R.sup.5 /R.sup.6等于烷基、(CH.sub.2).sub.1-6 COO-烷基、(CH.sub.2).sub.1-6 CONR.sup.10 R.sup.11、(CH.sub.2).sub.0-6 COOH、(CH.sub.2).sub.1-6 CO-烷基、CO.sub.2-烷基、烷基巯基烷基、烷基磺酰基、羟基烷基、巯基烷基、氨基烷基、N-(二)烷基氨基烷基或(CH.sub.2).sub.f Ar，其中f等于零至3；R.sup.7 /R.sup.8等于氢、烷基或苯基，m等于零至2，是杰出的降压药和解痉药。描述了制备过程和用途。
• A New Route for Protected Amino Alcohols from (<i>R</i>)-Glycidol. Copper(I) Mediated Alkylation of 4-Tosyloxymethyl-2-oxazolidinone
  作者：Seiji Iwama、Shigeo Katsumura

  DOI：10.1246/bcsj.67.3363

  日期：1994.12

  (S)-4-tosyloxymethyl-2-oxazolidinone, which was synthesized from (R)-glycidol through (R)-4-benzoyloxymethyl-2-oxazolidinone, with various lithium dialkylcuprate(I)s in THF proceeded smoothly to afford the corresponding protected amino alcohol derivatives in good yield.

  由（R）-缩水甘油经（R）-4-苯甲酰氧基甲基-2-恶唑烷酮合成的（S）-4-甲苯磺酰氧基甲基-2-恶唑烷酮与各种二烷基铜酸锂（I）在THF中的反应顺利进行以良好的收率得到相应的保护氨基醇衍生物。
• Palladium-Catalyzed Double and Single Carbonylations of<i>β</i>-Amino Alcohols. Selective Synthesis of Morpholine-2,3-diones and Oxazolidin-2-ones and Applications for Synthesis of<i>α</i>-Oxo Carboxylic Acids
  作者：Yasushi Imada、Yo Mitsue、Kazuo Ike、Ken-ichi Washizuka、Shun-Ichi Murahashi

  DOI：10.1246/bcsj.69.2079

  日期：1996.7

  Catalytic cross double carbonylation of secondary amines and alcohols proceeds in the presence of [PdCl2(MeCN)2] and CuI under carbon monoxide (80 atm) and oxygen (5 atm). Catalytic intramolecular double carbonylation of β-amino alcohols gives morpholine-2,3-diones, which are excellent protecting compounds of amino alcohols and important precursors for biologically active nitrogen compounds. In contrast

  仲胺和醇的催化交叉双羰基化在一氧化碳 (80 atm) 和氧气 (5 atm) 下在 [PdCl2(MeCN)2] 和 CuI 的存在下进行。β-氨基醇的催化分子内双羰基化得到吗啉-2,3-二酮，它是氨基醇的极好保护化合物和生物活性氮化合物的重要前体。相比之下，在一氧化碳和氧气 (1.0 atm) 的混合物 (1:1) 下，β-氨基醇的催化单羰基化进行选择性地得到恶唑烷-2-酮。该反应可以通过假设一种机制来解释，该机制包括（羟乙基）氨基羰基配体的羟基对氨基甲酰基钯 (II) 配合物的 CO 配体的分子内亲核攻击，然后还原消除得到吗啉-2,3-二酮。相反，羟基对氨基甲酰基的直接亲核攻击提供了恶唑烷-2-酮。作为双音和单音的常用中间体...

表征谱图